Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Apr 25, 2018
We Said Consumer Staples Would Underperform
The consumer staples sector has been pummeled by a number of factors, from long-term concerns about the adoption of new products in the tobacco industry to pressures on gross margins for branded consumables and generally underperforming free cash flows in the tried-and-true beverage arena. We still like the business models of many constituents, but you knew this was coming. Apr 24, 2018
Lockheed’s Shares Still Not Cheap
Image shown: "Lockheed Martin F-35 Joint Strike Fighter Lightning II test aircraft AA-1 undergoes flight testing over Fort Worth, Texas (source)." We liked Lockheed Martin’s first-quarter 2018 report, and we liked even more that the company raised its full-year outlook for revenue, operating income and earnings per share. Operating cash flow performance was weighed down by pension contributions and backlog didn’t advance in the period, but the backdrop for defense spending remains healthy given ongoing geopolitical tensions. Shares of Lockheed aren’t cheap, however. Apr 24, 2018
United Tech Ups Guidance; Outlook Bodes Well For Aerospace Supply Chain
Image Source: hj_west. We think activist pressure on United Technologies is unwarranted, and we were highly encouraged by the company’s execution during the first quarter of 2018. Performance at Pratt & Whitney and UTC Aerospace Systems bodes well for the aerospace supply chain. Apr 24, 2018
Coca-Cola’s Free Cash Flow Generation Could Be Better
Coca-Cola reported messy first-quarter 2018 results, making an assessment of its underlying free-cash-flow generation paramount. Coverage of cash dividends with free cash flow generation has become rather tight in recent years, and the company’s net debt position isn’t exactly encouraging. Very few companies have the competitive advantages and dividend growth track record of this tried-and-true beverage giant, however. Apr 23, 2018
Alphabet May Need to Clean Up Its Spending
Alphabet, the company formerly known as Google, put up decent first-quarter 2018 results with respect to the top line, but the company is facing a rising cost and capital-spending profile. The first quarter could have been a lot better, in our opinion. Apr 23, 2018
Market Not Overreacting to Hasbro’s Miss; Shares Up
Toy giant Hasbro turned in a poor first-quarter report April 23, but the market is not overreacting as the issues weighing on its performance are largely transient, in our view. Apr 23, 2018
Incyte’s Ongoing Disappointments and Ultragenyx’s Exciting Development
Image shown: Ultragenyx's promising pipeline of opportunities. Ultragenyx March 2018 Presentation. The pharma/biotech sector, unlike other mainline industries, is driven by the clinical data readouts on the next-gen molecules in the clinical pipeline. We have witnessed many exaggerated moves with an often-binary outcome on the smaller single molecule entities, but we also have witnessed a negligible impact on the broader, more-diverse industry behemoths. We wanted to touch on a few recent data readouts to illustrate the volatile, risky yet potentially lucrative nature of the industry. Apr 20, 2018
General Electric Gets a Boost; Honeywell Hikes Guidance
Image Source: Jeff Turner. General Electric continues to struggle, but its first quarter earnings report came in better than expected as demand across many of its business was positive. We still have no interest in shares. Meanwhile, Honeywell continues to power ahead as it raised its top- and bottom-line guidance for the full year 2018, reflecting a similarly positive demand profile. Apr 20, 2018
Reiterating Our Positive View on Apple
We continue to include Apple in both newsletter portfolios. Very few companies have the balance-sheet strength and free-cash-flow generation that Apple does. Apr 19, 2018
Procter & Gamble Pressured By Pricing
Image Source: MrTinDC. Recently transformed consumer staples giant Procter & Gamble’s fiscal 2018 third quarter report left a bit to be desired as pricing woes weighed on organic top-line performance. The company is also shifting its Consumer Health business as it has agreed to acquire Merck KGaA, Darmstadt, Germany’s Consumer Health business.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|